BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 7531902)

  • 1. Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord.
    Gonzalez-Barcena D; Vadillo-Buenfil M; Cortez-Morales A; Fuentes-Garcia M; Cardenas-Cornejo I; Comaru-Schally AM; Schally AV
    Urology; 1995 Feb; 45(2):275-81. PubMed ID: 7531902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer.
    Gonzalez-Barcena D; Vadillo-Buenfil M; Gomez-Orta F; Fuentes Garcia M; Cardenas-Cornejo I; Graef-Sanchez A; Comaru-Schally AM; Schally AV
    Prostate; 1994; 24(2):84-92. PubMed ID: 7508623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
    Jungwirth A; Galvan G; Pinski J; Halmos G; Szepeshazi K; Cai RZ; Groot K; Schally AV
    Prostate; 1997 Aug; 32(3):164-72. PubMed ID: 9254895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge.
    Leroy I; d'Acremont M; Brailly-Tabard S; Frydman R; de Mouzon J; Bouchard P
    Fertil Steril; 1994 Sep; 62(3):461-7. PubMed ID: 8062939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.
    Jungwirth A; Pinski J; Galvan G; Halmos G; Szepeshazi K; Cai RZ; Groot K; Vadillo-Buenfil M; Schally AV
    Eur J Cancer; 1997 Jun; 33(7):1141-8. PubMed ID: 9376196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained suppression of serum LH, FSH and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal men.
    Behre HM; Böckers A; Schlingheider A; Nieschlag E
    Clin Endocrinol (Oxf); 1994 Feb; 40(2):241-8. PubMed ID: 8137524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men.
    Behre HM; Klein B; Steinmeyer E; McGregor GP; Voigt K; Nieschlag E
    J Clin Endocrinol Metab; 1992 Aug; 75(2):393-8. PubMed ID: 1639941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
    Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth.
    Krakowsky Y; Morgentaler A
    Eur Urol Focus; 2019 Jan; 5(1):81-89. PubMed ID: 28753828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recovery of Serum Testosterone Levels and Sexual Function in Patients Treated With Short-term Luteinizing Hormone-releasing Hormone Antagonist as a Neoadjuvant Therapy Before External Radiotherapy for Intermediate-risk Prostate Cancer: Preliminary Prospective Study.
    Inoue T; Mizowaki T; Kabata D; Shintani A; Terada N; Yamasaki T; Negoro H; Kobayashi T; Nakamura K; Inokuchi H; Ogawa O
    Clin Genitourin Cancer; 2018 Apr; 16(2):135-141.e1. PubMed ID: 29051056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer.
    Raddin RS; Walko CM; Whang YE
    Anticancer Drugs; 2011 Mar; 22(3):299-302. PubMed ID: 21360851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Pinski J; Halmos G; Szepeshazi K; Schally AV
    Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
    Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
    Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recovery of pituitary-gonadal function in male rats after long-term suppression induced by a single injection of microcapsules of LH-RH antagonist cetrorelix (SB-75).
    Pinski J; Yano T; Szepeshazi K; Groot K; Schally AV
    J Androl; 1993; 14(3):164-9. PubMed ID: 8407570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.
    Bruchovsky N; Goldenberg SL; Akakura K; Rennie PS
    Cancer; 1993 Sep; 72(5):1685-91. PubMed ID: 7688656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix.
    Halmos G; Schally AV; Pinski J; Vadillo-Buenfil M; Groot K
    Proc Natl Acad Sci U S A; 1996 Mar; 93(6):2398-402. PubMed ID: 8637885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors.
    Lamharzi N; Schally AV; Koppán M
    Regul Pept; 1998 Oct; 77(1-3):185-92. PubMed ID: 9809814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.
    Korkut E; Bokser L; Comaru-Schally AM; Groot K; Schally AV
    Proc Natl Acad Sci U S A; 1991 Feb; 88(3):844-8. PubMed ID: 1992476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hormonal status in patients with advanced prostatic cancer on the therapy with androgen blockade].
    Vojinov S; Levakov I; Jeremić D; Zivojinov S; Marusić G
    Vojnosanit Pregl; 2011 Apr; 68(4):321-6. PubMed ID: 21630520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB; Mottet N
    BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.